...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer (R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer
【24h】

Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer (R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer

机译:用CheckpointTyper测定测量的PD-L1 mRNA表达与非小细胞肺癌中的免疫组化评估的PD-L1蛋白表达测定

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Immunohistochemical (IHC) assessment of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) has become important since the development of anti-PD-1/-PD-L1 directed drugs. Various PD-L1 antibodies and cut-offs have been used in different trials to predict response to these drugs, thus comparison of those studies is difficult. We compared PD-L1 mRNA expression measured by RT-qPCR with PD-L1 protein expression evaluated by IHC. Moreover, we investigated the impact of different tumour tissue acquisition methods on the reliability of PD-L1 measurement techniques. Materials and Methods: NSCLC cases (N=22), including n=9 mediastinal lymph node biopsies acquired by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and n=5 metastases, were evaluated prospectively for PD-L1 protein on tumor cells (TC) and immune cells (IC) using E1L3N and 28-8 antibodies and PD-L1 mRNA using the CheckPoint TYPER (R) assay. Results: In primary NSCLC tissues, agreement between PD-L1 mRNA and TC staining using the 28-8 antibody was excellent (kappa=0.85, p=0.0002). Comparing both PD-L1 antibodies against each other showed a kappa value of 0.58 (p=0.0106). In EBUS-TBNA, PD-L1 mRNA correlated perfectly with the 28-8 antibody (kappa=1.0, p=0.0023). PD-L1 mRNA levels significantly differed when comparing 28-8 TC staining of tumours >49% with 1-49% and 0% (p=0.0040; p=0.0081, respectively). In metastatic lesions, differences between PD-L1 mRNA and IHC became apparent (kappa=0.2, p=0.2525). Conclusion: Testing of PD-L1 mRNA and 28-8 IHC showed an excellent agreement in NSCLC samples including mediastinal lymph node biopsies. Since PD-L1 expression in >50% TC detected by 28-8 IHC can be reliably detected by RT-qPCR, quantitative PD-L1 mRNA determination should be considered as an alternative to IHC as there is no interobserver variability in RNA results.
机译:背景:非小细胞肺癌(NSCLC)中编程死亡配体1(PD-L1)的免疫组织化学(IHC)评估已成为抗PD-1 / -PD-L1指向药物的发展。在不同的试验中使用了各种PD-L1抗体和截止值以预测对这些药物的反应,因此这些研究的比较难以实现。我们将通过RT-QPCR测量的PD-L1 mRNA表达与IHC评价的PD-L1蛋白表达进行了比较了通过RT-QPCR测量。此外,我们研究了不同肿瘤组织采集方法对PD-L1测量技术可靠性的影响。材料和方法:NSCLC病例(n = 22),包括N = 9肿瘤引导的横向针吸附(EBUS-TBNA)和N = 5转移的N = 9纵隔淋巴结活组织检查,对肿瘤的PD-L1蛋白预先评估PD-L1蛋白使用E1L3N和28-8抗体和PD-L1 mRNA的细胞(Tc)和免疫细胞(IC)使用检查点Typer测定。结果:在初级NSCLC组织中,使用28-8抗体的PD-L1 mRNA和TC染色之间的一致性(Kappa = 0.85,P = 0.0002)。将PD-L1抗体彼此相对比较显示κ值为0.58(p = 0.0106)。在EBUS-TBNA中,PD-L1 mRNA与28-8抗体完全相关(Kappa = 1.0,P = 0.0023)。当肿瘤的28-8吨TC染色时,PD-L1 mRNA水平显着不同> 49%,1-49%和0%(p = 0.0040; p = 0.0081)。在转移性病变中,PD-L1 mRNA和IHC之间的差异变得显而易见(Kappa = 0.2,P = 0.2525)。结论:PD-L1 mRNA和28-8 IHC检测在包括纵隔淋巴结活检的NSCLC样品中显示出优异的一致性。由于通过RT-QPCR可靠地检测到28-8 IHC的PD-L1表达> 50%TC,因此应将定量PD-L1 mRNA测定视为IHC的替代方法,因为RNA结果没有Interobserver可变性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号